Zentiva Launches First Biosimilar Monoclonal Antibody Across EU

December 01, 2025
Zentiva has introduced its first biosimilar monoclonal antibody in the European Union, marking the company's entry into the biosimilars market following EMA approval.

Zentiva has launched its first biosimilar monoclonal antibody across the European Union after receiving approval from the European Medicines Agency, announced in a press release.

The biosimilar is used for treating bone-related diseases and was approved through the EMA's centralized procedure. Distribution to European markets will begin in December 2025.

This marks Zentiva's entry into the biosimilars segment as part of its broader strategy to expand beyond traditional generics. The company stated that the move supports sustainable growth in the biologics sector, one of the fastest-growing areas in pharmaceuticals.

We hope you enjoyed this article.

Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.

Also, consider following us on social media:

Healthcare & Life Sciences AI AI Brief AI Brief (X)

More from: Life Sciences

12/03
FDA Introduces Agentic AI Platform for Staff Workflows
12/03
Medint Study Finds AI Misses Key Nuances in Complex Clinical Decisions
12/03
Linus Health to Present AI Tools for Early Alzheimer’s Detection at CTAD 2025
12/03
Dastify Solutions Report Predicts 40% Drop in Medical Claim Denials with AI in 2025
12/03
Dastify Solutions Report Predicts 40% Reduction in Medical Claim Denials Through AI in 2025

Subscribe to Life AI Weekly

Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.

AI Token Webinar

Industry analysis

2025 Global Business Services Agenda: Gen AI Takes Center Stage

The Hackett Group

This industry analysis by The Hackett Group explores the transformative impact of generative artificial intelligence (Gen AI) on global business services (GBS) in 2025. The study highlights the shift from exploration to acceleration of Gen AI initiatives, with 89% of executives advancing these projects to improve customer satisfaction, innovate products, and reduce costs. The report also discusses the challenges and strategies for successful Gen AI adoption, emphasizing the need for a technology-enabled operating model and the importance of reskilling the workforce.

Read more

You May Also Like